GSK is winning 70% of the RSV market, while Pfizer's launch has left it ‘disappointed’ so far
GSK has taken over a significant share of what’s expected to be a multibillion-dollar market for RSV preventatives, turning its vaccine into a blockbuster in the first year on the market while competitors struggle.
Like GSK, Pfizer also had its RSV vaccines approved this year, and Sanofi and AstraZeneca’s preventive antibody was cleared by the FDA in July. The Northern Hemisphere is in the height of RSV season, and there’s been significant demand for the products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
